Your browser doesn't support javascript.
loading
Development of taste-masking microcapsules containing azithromycin by fluid bed coating for powder for suspension and in vivo evaluation.
Dung, Pham-Thi-Phuong; Trinh, Thanh-Dat; Nguyen, Quoc-Hoai; Nguyen, Huu-Manh; Nguyen, Ngoc-Chien; Tran, Ngoc-Bao; Tran, Cao-Son; Nguyen, Thi-Hong-Ngoc; Tung, Nguyen-Thach.
Afiliação
  • Dung PT; Department of Pharmaceutics, Hanoi University of Pharmacy, Hanoi, Vietnam.
  • Trinh TD; Faculty of Pharmacy, Dai Nam University, Hanoi, Vietnam.
  • Nguyen QH; Department of Pharmaceutics, Hanoi University of Pharmacy, Hanoi, Vietnam.
  • Nguyen HM; Department of Pharmaceutics, Hanoi University of Pharmacy, Hanoi, Vietnam.
  • Nguyen NC; Department of Pharmaceutics, Hanoi University of Pharmacy, Hanoi, Vietnam.
  • Tran NB; Department of Pharmaceutics, Hanoi University of Pharmacy, Hanoi, Vietnam.
  • Tran CS; Department of Pharmaceutics, Hanoi University of Pharmacy, Hanoi, Vietnam.
  • Nguyen TH; National Institute for Food Control, Hanoi, Vietnam.
  • Tung NT; National Institute for Food Control, Hanoi, Vietnam.
J Microencapsul ; 40(5): 345-356, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37129865
ABSTRACT
This research aims to develop bitter taste-masking microcapsules containing azithromycin (AZI) by a simpler and familiar method, fluid-bed coating technology, in comparison with Zithromax®. Cores of microcapsules, AZI microparticles, were prepared by fluid-bed granulation, then taste-masking polymer was covered on by fluid-bed coating technique. Eudragit L100, Eudragit RL100, and ethyl cellulose in single and combined with Eudragit L100 and Eudragit E100 were used as taste-masking polymers. The obtained microcapsules were characterised by taste-masking ability, in vitro release, SEM, coating thickness, and coating efficiency. Combination of ethyl cellulose and Eudragit E100 (31) in coating thickness of 45.13 ± 2.12% w/w prevents AZI release from microcapsules below bitter taste threshold (1.78 ± 1.17 µg/ml). Bioavailability of powders containing AZI microcapsules and pH modulators (50 mg Na3PO4 and 35 mg Mg(OH)2) was not significantly different from the reference product (Zithromax®, Pfizer, New York, NY) in the rabbit model (p > 0.05). These results support the possibility of developing a generic product containing AZI.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Paladar / Azitromicina Limite: Animals Idioma: En Revista: J Microencapsul Assunto da revista: FARMACIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Vietnã

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Paladar / Azitromicina Limite: Animals Idioma: En Revista: J Microencapsul Assunto da revista: FARMACIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Vietnã